Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jaguar Animal Health ( (JAGX) ) has issued an update.
On February 18, 2026, Jaguar Health announced that its board had declared a one-time special stock dividend of Series O convertible preferred shares for holders of its common stock and certain warrants of record on March 2, 2026, with payment scheduled for March 4, 2026. The non-transferable preferred stock, which carries no regular dividends or listing, is designed to convert into common shares by December 31, 2026 at a value tied to market price, with a stated goal of offering existing shareholders dilution protection as the company evaluates options to repay and restructure its debt.
Management framed the special dividend as a reward for long-term investors and a tool to mitigate potential dilution arising from future capital actions linked to debt reduction. The move comes as Jaguar advances a sharply focused rare-disease pipeline centered on crofelemer for intestinal failure, backed by early proof-of-concept data in microvillus inclusion disease and short bowel syndrome, and follows non-dilutive capital received in January 2026 under a U.S. license deal for Mytesi with Future Pak, highlighting its reliance on partnerships while balancing capital structure risk for stakeholders.
The most recent analyst rating on (JAGX) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses, high leverage, and heavy cash burn) and a bearish technical setup (trading below all major moving averages with negative MACD). Corporate events provide a meaningful positive offset via non-dilutive funding and encouraging clinical progress, but not enough to overcome current financial and trend risks.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health is a commercial-stage pharmaceuticals company focused on developing novel, plant-derived prescription medicines for gastrointestinal distress in humans and animals, sourced sustainably from rainforest botanicals. Through subsidiaries Napo Pharmaceuticals and Napo Therapeutics, it targets rare and orphan intestinal failure disorders such as microvillus inclusion disease and short bowel syndrome using crofelemer powder-for-oral solution.
Crofelemer, its lead product, is an oral plant-based medicine purified from the sap of the Croton lechleri tree, harvested under fair trade practices to support ecological integrity and indigenous communities. Jaguar’s strategy emphasizes non-dilutive partnerships and global development programs for crofelemer in severe pediatric and adult intestinal failure indications, positioning the group in niche rare-disease gastroenterology markets.
Average Trading Volume: 3,812,034
Technical Sentiment Signal: Sell
Current Market Cap: $2.36M
For an in-depth examination of JAGX stock, go to TipRanks’ Overview page.